- Home
- LNKB vs VNDA Comparison
LNKB vs VNDA Comparison
Compare LNKB & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNKB
- VNDA
- Stock Information
- Founded
- LNKB 2018
- VNDA 2002
- Country
- LNKB United States
- VNDA United States
- Employees
- LNKB N/A
- VNDA N/A
- Industry
- LNKB
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- LNKB
- VNDA Health Care
- Exchange
- LNKB Nasdaq
- VNDA Nasdaq
- Market Cap
- LNKB 256.4M
- VNDA 261.7M
- IPO Year
- LNKB N/A
- VNDA 2006
- Fundamental
- Price
- LNKB $7.53
- VNDA $4.89
- Analyst Decision
- LNKB Strong Buy
- VNDA Strong Buy
- Analyst Count
- LNKB 1
- VNDA 3
- Target Price
- LNKB $9.00
- VNDA $15.33
- AVG Volume (30 Days)
- LNKB 65.5K
- VNDA 422.8K
- Earning Date
- LNKB 07-28-2025
- VNDA 07-30-2025
- Dividend Yield
- LNKB 3.95%
- VNDA N/A
- EPS Growth
- LNKB N/A
- VNDA N/A
- EPS
- LNKB 0.97
- VNDA N/A
- Revenue
- LNKB $120,786,000.00
- VNDA $201,351,000.00
- Revenue This Year
- LNKB $21.23
- VNDA $16.86
- Revenue Next Year
- LNKB N/A
- VNDA $39.78
- P/E Ratio
- LNKB $7.84
- VNDA N/A
- Revenue Growth
- LNKB 135.60
- VNDA 13.37
- 52 Week Low
- LNKB $6.00
- VNDA $3.81
- 52 Week High
- LNKB $7.98
- VNDA $6.37
- Technical
- Relative Strength Index (RSI)
- LNKB 63.84
- VNDA 64.92
- Support Level
- LNKB $6.67
- VNDA $4.66
- Resistance Level
- LNKB $7.70
- VNDA $4.95
- Average True Range (ATR)
- LNKB 0.25
- VNDA 0.15
- MACD
- LNKB 0.07
- VNDA 0.02
- Stochastic Oscillator
- LNKB 85.22
- VNDA 89.47
About LNKB LINKBANCORP Inc.
Linkbancorp Inc operates in the banking industry. It provides banking services for individuals and businesses such as commercial lending, non-profit banking, treasury management, deposits and loans. Company portfolio segments includes: Agriculture and farmland, Construction, Commercial & industrial, Commercial real estate, Residential real estate, Municipal, customers and Other loans.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.